Data from the Prostate Lung Colorectal and Ovarian (PLCO) trial did not show a survival benefit from screening, however the European Randomized Study of Prostate Cancer (ERSPC) trial demonstrated a 31% reduction in the risk of death from prostate cancer in men that had PSA screening [36]. Here, KLK3 is linked to prostate carcinoma.